ONPATTRO®


 
 
 
 
 
 
 
 
 


 

ONPATTRO® (Patisiran) is a double-stranded small interfering ribonucleic acid targeted to hepatocytes for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

ONPATTRO® is manufactured by Almylam.

Administration and Dosage:

Onpattro is an intravenous infusion every 3 weeks.

Common Side Effects:

The more common side effects of ONPATTRO® include respiratory infections, such as colds, sinus infections, and nasal congestion, and infusion-related reactions.

More Information:

Please read the full Prescribing Information for ONPATTRO® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

ONPATTRO® is indicated to treat:

  • Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis